國家衛生研究院 NHRI:Item 3990099045/9589
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 917195      線上人數 : 1462
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9589


    題名: A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
    作者: Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y
    貢獻者: Division of Clinical Trial Statistics;National Institute of Cancer Research
    摘要: Background: Fluorouracil and platinum can be considered a standard option for advanced gastric cancer (AGC). Docetaxel is also an effective agent with no cross-resistance with fl uorouracil and platinum. Concomitant combination of docetaxel with fl uorouracil and platinum had been explored, but demonstrated intolerable toxicities. A different way to include all active agents in fi rst-line treatment of gastric adenocarcinoma may be to use them sequentially. We aimed to evaluate the activity and the safety pro file of sequential chemotherapy with capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in the fi rst-line treatment of AGC. Methods: We conducted a phase II study of fi rst-line sequential chemotherapy in AGC. Treatment consisted of six cycles of capecitabine plus oxaliplatin (XELOX; capecitabine 1000 mg/m 2 bid on days 1 – 10 and oxaliplatin 85 mg/m 2 on day 1; Q2W) followed by four cycles of docetaxel plus capecitabine (TX; docetaxel 30 mg/m 2 on D1 and D8; capecitabine 825 mg/m 2 bid on days 1 – 14; Q3W). Primary endpoint was the objective response rate. Results: Fifty-one patients were enrolled: median age 63 years, male/female: 37/14. Main grade 3 – 4 toxicities were ANC decreased (25.5%), diarrhea (11.8%), hand-foot syndrome (15.7%), and anemia (11.8%). The objective response rate was 61.7%. Median PFS and OS were 8.6 and 11.0 months; respectively. Conclusions: This sequential treatment demonstrated feasibility with a favorable safety pro fi le and produced encouraging results in terms of activity and ef fi cacy.
    日期: 2015-12
    關聯: Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99.
    Link to: http://dx.doi.org/10.1111/jgh.13188
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0815-9319&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000365677200256
    顯示於類別:[蕭金福] 會議論文/會議摘要
    [劉滄梧] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000365677200256.pdf105KbAdobe PDF606檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋